Redwood City, California – November 1, 2016 – Synthego, a leading provider of genome engineering solutions, today announces the use of its CRISPRevolution synthetic RNA in nine of the top 10 biology and biochemistry universities around the globe. These world-class institutions are using Synthego’s products in CRISPR research on stem cells, adherent cell lines and mouse embryos. In addition to being widely used by top research institutions, Synthego’s products are also shipping to 31 countries and growing, bringing consistent high editing efficiencies to CRISPR scientists globally.
The world’s top 10 life sciences institutions using Synthego products include Harvard, MIT, UC Berkeley, Stanford, UC San Francisco, University of Cambridge, UC San Diego, Johns Hopkins and Cornell. Other leading institutions using Synthego products include UCLA, Eberhard Karls Universität Tübingen, Seattle Children’s Research Institute, Universität Zürich and Universiteit Gent.
Seattle Children’s Research Institute, for example, is using Synthego’s sgRNA kit to find a cure for pediatric hemoglobinopathies and immune deficiency diseases. And the University of California, Berkeley Patel Lab, is using the product to research early regulatory patterning genes.
I was first introduced to Synthego when teaching a summer course at Woods Hole in developmental biology. We wanted to work on CRISPR gene editing, but didn’t have the time or labor to prepare guide RNA using the IVT process,” said Erin Jarvis, PhD candidate, Evolutionary Development Biology, UC Berkeley’s Patel Lab. “Synthego provided the synthetic RNA in several days, requiring no annealing, and it sped up our process in the classroom. Now, I’ve taken that knowledge to our lab, and we’ve been using Synthego’s synthetic sgRNA for months. It continues to expedite my research while providing consistent trials and significant survival rates compared to my IVT guides.
By reducing the barriers to consistent, highly efficient and cost-effective CRISPR research, Synthego is helping top research institutions conduct experiments more rapidly and with better results,” said Paul Dabrowski, CEO of Synthego. “We are honored to play a part in the research of the world’s top institutions by providing a vital component for their experiments. CRISPR has the potential to revolutionize personalized medicine and treatments for cancer and inherited diseases, and our synthetic CRISPR RNA aims to help researchers get there faster.
Synthego is focused on delivering products with the highest editing efficiency, fastest turnaround time, and lowest costs for scientists. The company’s flagship product line, CRISPRevolution, is the world’s leading synthetic CRISPR RNA portfolio and includes EZ RNA Kits, sgRNA, custom and modified RNA, and pre-designed libraries.
For more information about Synthego and its products, visit www.synthego.com/products.
Founded by former SpaceX engineers, Synthego is a leading provider of genome engineering solutions. The company’s flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Headquartered in Silicon Valley, California, Synthego customers include leading institutions around the world including countries such as Australia, Belgium, Germany, UK, USA and Switzerland.